A COVID-19 vaccine developed by Sanofi and GlaxoSmithKline showed a robust immune response in early-stage clinical trial results, enabling them to move to a late-stage study, the companies announced on Monday. France's Sanofi and U.K.-based GSK said a global Phase 3 trial would start in the coming weeks and involve more than 35,000 adults. The goal is for the vaccine to be approved by the fourth quarter after having initially targeted the first half of this year before a setback. Canada has an agreement for up to 72 million doses of the vaccine, pending Health Canada authorization. Earlier this year, Sanofi also announced investments to boost Canadian vaccine manufacturing, facilitating the creation of hundreds of jobs and millions in funding annually for research and development.

Source: CBC News May 17, 2021 15:33 UTC